uniQure NV (QURE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

QURE uniQure NV

Watchlist

7.790
+0.360+4.85%

Close Nov 8 16:00 ET

7.790
0.0000.00%

Post 20:01 ET

379.71MMarket Cap-1573P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $12
Moomoo NewsNov 8 10:31 ET · Ratings
UniQure N.V. (NASDAQ:QURE) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Simply Wall StNov 8 05:08 ET
Cantor Fitzgerald Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $28
Moomoo NewsNov 6 13:31 ET · Ratings
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Cuts Target Price to $9
Moomoo NewsNov 6 13:31 ET · Ratings
Express News | Goldman Sachs Maintains Neutral on UniQure, Lowers Price Target to $9
BenzingaNov 6 12:29 ET
UniQure Is Maintained at Outperform by RBC Capital
Dow JonesNov 6 12:22 ET · Ratings

Comments

Tonyco

Oct 17 10:54

$CuriosityStream (CURI.US)$
I went with the wrong Curi! lol, both are good LT though
$uniQure NV (QURE.US)$

Stock_Drift

Oct 4 14:13

Gainer Ticks. 3:12pm EST.10/4/24

$uniQure NV (QURE.US)$ $Apogee Enterprises (APOG.US)$ $Capricor Therapeutics (CAPR.US)$ $noco-noco (NCNC.US)$ $UP Fintech (TIGR.US)$ $JBDI Holdings (JBDI.US)$ $Snail (SNAL.US)$ $Cue Biopharma (CUE.US)$ $Entero Therapeutics (ENTO.US)$ $Power REIT (PW.US)$ $Ford Motor (F.US)$ $Beneficient (BENF.US)$ $Phoenix Motor (PEV.US)$ $Chanson International (CHSN.US)$
📊⚡️📊

Stock_Drift

Sep 23 06:10

$uniQure NV (QURE.US)$

Jaguar8

Sep 23 06:06

NEWS

$uniQure NV (QURE.US)$
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) announced that the U.S. FDA has granted Orphan Drug Designation to AMT-191, their investigational gene therapy for Fabry disease. This follows the dosing of the first patient in a U.S. multi-center, open-label Phase I/IIa trial in August 2024. AMT-191 is a one-time intravenously administered AAV5-based gene therapy targeting the liver to produce G...

Jaguar8

Aug 15 07:56

NEWS

$uniQure NV (QURE.US)$
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) has initiated dosing in a Phase I/IIa clinical trial of AMT-191 for Fabry diseasetreatment. The multi-center, open-label trial in the US will assess safety, tolerability, and early efficacy signs in two dose-escalating cohorts. AMT-191 is an AAV5-based gene therapy delivering a galactosidase alpha (GLA) transgene to the live...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

QURE uniQure NV

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target